MPV17 Gene - MPV17 Mitochondrial Inner Membrane Protein

📖 Wiki Page

gene1918 wordssynced 2026-04-02

MPV17 Gene - MPV17 Mitochondrial Inner Membrane Protein

<div class="infobox infobox-gene">
<h3>MPV17</h3>
<table>
<tr><th>Full Name</th><td>MPV17 Mitochondrial Inner Membrane Protein</td></tr>
<tr><th>Gene Symbol</th><td>MPV17</td></tr>
<tr><th>Chromosomal Location</th><td>2p23.3</td></tr>
<tr><th>NCBI Gene ID</th><td>[4350](https://www.ncbi.nlm.nih.gov/gene/4350)</td></tr>
<tr><th>OMIM</th><td>[604933](https://www.omim.org/entry/604933)</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000104147</td></tr>
<tr><th>UniProt</th><td>[Q9NPJ3](https://www.uniprot.org/uniprot/Q9NPJ3)</td></tr>
<tr><th>Protein Length</th><td>176 amino acids</td></tr>
<tr><th>Associated Diseases</th><td>[Mitochondrial DNA Depletion Syndrome](/diseases/mitochondrial-dna-depletion-syndrome), [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Hepatocerebral Syndrome</td></tr>
</table>
</div>

Introduction

The MPV17 gene encodes MPV17 Mitochondrial Inner Membrane Protein, a critical component of the mitochondrial inner membrane that plays an essential role in maintaining mitochondrial DNA (mtDNA) integrity and copy number. MPV17 is a highly conserved mitochondrial protein that functions as a key regulator of mtDNA maintenance, and mutations in this gene are a well-established cause of mitochondrial DNA depletion syndrome (MTDPS), a severe multisystem disorder typically presenting in early childhood[@spinazzi2009][@elhattab2017].

...

MPV17 Gene - MPV17 Mitochondrial Inner Membrane Protein

Introduction

Beyond its established role in MTDPS, emerging research has implicated MPV17 dysfunction in the pathogenesis of major neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). Mitochondrial dysfunction is a hallmark of these age-related neurodegenerative conditions, and the pathways regulated by MPV17 may provide important insights into disease mechanisms and therapeutic strategies[@moreno2019][@barg2020].

Overview

Mermaid diagram (expand to render)

MPV17 is a small (176 amino acids) mitochondrial inner membrane protein that was initially identified as a target for insertional mutagenesis in mice, where it was found to cause a "mongoose" phenotype characterized by mitochondrial DNA depletion. Subsequent studies established that MPV17 is essential for the maintenance of mtDNA in humans, with loss-of-function mutations leading to severe and often fatal mitochondrial disorders.

The protein localizes to the mitochondrial inner membrane where it forms a homomeric complex that likely functions as a channel or transporter. While the exact molecular function of MPV17 remains incompletely understood, evidence suggests it plays a crucial role in regulating the mitochondrial nucleoid environment, possibly by controlling the import of nucleotides or other metabolites required for mtDNA replication and maintenance["@parisi2009"].

MPV17 deficiency results in a dramatic reduction in mtDNA copy number across multiple tissues, particularly affecting high-energy-demand organs such as liver, brain, and skeletal muscle. This leads to the clinical syndrome of mitochondrial DNA depletion syndrome (MTDPS), which manifests as hepatopathy, neurological dysfunction, and often early mortality["@wong2007"][@karadimas2006].

Molecular Function

Protein Structure

MPV17 is a small inner membrane protein with a characteristic architecture:

| Feature | Details |
|---------|---------|
| Molecular weight | ~20 kDa |
| Topology | Type II inner membrane protein |
| Transmembrane domains | 3 predicted helices |
| N-terminal | Facing mitochondrial matrix |
| C-terminal | Facing intermembrane space |

Structural characteristics:

Multiple transmembrane helices: MPV17 contains three predicted transmembrane helices that anchor it in the mitochondrial inner membrane
N-terminal matrix-facing domain: Contains functional motifs important for protein interactions
Homomeric assembly: Forms higher-order complexes in the inner membrane

Role in Mitochondrial DNA Maintenance

MPV17 plays several critical roles in mtDNA maintenance[@uusimaa2013]:

Nucleotide Pool Regulation

Mitochondrial nucleotide balance: MPV17 may regulate the import or availability of deoxynucleotides in the mitochondrial matrix

dNTP synthesis: Interactions with mitochondrial dNTP salvage pathways

Replication support: Provides appropriate nucleotide conditions for mtDNA replication

mtDNA Replication Complex

Nucleoid organization: MPV17 influences the structure and distribution of mitochondrial nucleoids
Replication machinery: Supports the function of the mtDNA replication machinery
Quality control: Helps maintain mtDNA integrity during replication

Mitochondrial Dynamics

Morphology regulation: MPV17 affects mitochondrial shape and distribution
Energy metabolism: Supports proper mitochondrial respiration and ATP production
Cellular stress response: Involved in mitochondrial stress signaling

Interaction Network

MPV17 interacts with several mitochondrial proteins:

| Partner | Interaction | Functional Role |
|---------|-------------|-----------------|
| TFAM | Indirect | mtDNA packaging |
| POLG | Indirect | mtDNA replication |
| Twinkle | Indirect | mtDNA helicase |
| Mitochondrial ribosomes | Indirect | mtDNA expression |

Role in Disease

Mitochondrial DNA Depletion Syndrome

MPV17 mutations cause a specific form of MTDPS known as hepatocerebral syndrome[@kaji2018][@dalla2017]:

Genetics

Inheritance: Autosomal recessive
Mutation types: Missense, nonsense, splice-site, deletions
Hotspots: No clear mutation hotspots; distributed throughout gene
Founder mutations: Certain populations have specific founder variants

Clinical Features

| System | Manifestation | Onset |
|--------|---------------|-------|
| Hepatic | Liver failure, cholestasis, hepatic steatosis | Infancy |
| Neurological | Developmental delay, hypotonia, ataxia | Infancy |
| Gastrointestinal | Failure to thrive, vomiting | Infancy |
| Metabolic | Lactic acidosis, hypoglycemia | Variable |
| Ophthalmologic | Ophthalmoplegia, optic atrophy | Sometimes |

Pathogenesis

mtDNA depletion: Primary defect is severe reduction in mtDNA copy number

Respiratory chain deficiency: Reduced mtDNA leads to impaired oxidative phosphorylation

Tissue-specific vulnerability: High-energy tissues most affected

Secondary mechanisms: Oxidative stress, apoptosis, metabolic failure

Alzheimer's Disease

Emerging evidence links MPV17 to AD pathogenesis[@chaves2020]:

Mitochondrial Dysfunction

mtDNA alterations: Changes in mtDNA copy number and integrity in AD brain
Energy failure: Impaired oxidative phosphorylation in AD neurons
Mitochondrial dynamics: Altered fission/fusion in AD

Molecular Mechanisms

mtDNA maintenance: MPV17 dysfunction may contribute to mtDNA abnormalities

Oxidative stress: Mitochondrial dysfunction increases ROS production

Amyloid interactions: Aβ affects mitochondrial function through multiple pathways

Tau pathology: Mitochondrial dysfunction synergizes with tau pathology

Therapeutic Implications

Mitochondrial protectants: Compounds that support mitochondrial function
Nucleotide supplementation: Potential metabolic interventions
Gene therapy: Future therapeutic approaches

Parkinson's Disease

MPV17 dysfunction is relevant to PD through[@kruszewski2020]:

Mitochondrial Involvement

mtDNA mutations: Rare mtDNA variants associated with PD
Complex I deficiency: Commonly observed in PD substantia nigra
PINK1/Parkin pathway: Mitochondrial quality control defects

Mechanisms

Dopaminergic vulnerability: High energy demands make neurons susceptible

Alpha-synuclein: Mitochondrial dysfunction may promote α-syn aggregation

LRRK2 interactions: Mitochondrial pathways affected by LRRK2 mutations

Research Evidence

Mitochondrial dysfunction is a key feature of PD pathogenesis
MPV17-related pathways may be relevant to idiopathic PD
Therapeutic targeting of mitochondria is an active research area

Other Mitochondrial Disorders

MPV17 deficiency belongs to a broader group of mtDNA depletion syndromes:

| Syndrome | Gene | Phenotype |
|----------|------|------------|
| MTDPS type I (hepatocerebral) | TK2 | Myopathic |
| MTDPS type III (hepatocerebral) | DGUOK | Hepatic/neurological |
| MTDPS type IV (neurological) | RRMM2 | Encephalomyopathic |
| MTDPS type V (myopathic) | TK2 | Myopathic |
| MTDPS type VI (hepatocerebral) | MPV17 | Hepatic/neurological |

Expression Pattern

Tissue Distribution

MPV17 is expressed ubiquitously with highest levels in high-energy-demand tissues:

| Tissue | Expression Level | Relevance |
|--------|------------------|-----------|
| Liver | Very high | Primary disease target |
| Brain | High | Neurological involvement |
| Skeletal muscle | High | Myopathic features |
| Heart | Moderate | Variable involvement |
| Kidney | Moderate | Variable involvement |
| Fibroblasts | Variable | Diagnostic tissue |

Cellular Localization

Mitochondria: Inner membrane protein
Submitochondrial: Embedded in inner membrane with matrix-facing domains
Nucleoid association: Associated with mtDNA nucleoids

Developmental Regulation

Embryonic: Expressed throughout development
Postnatal: Maintained expression in all tissues
Cell-type specific: Higher in cells with high metabolic demands

Therapeutic Implications

Current Treatment Approaches

| Approach | Status | Notes |
|----------|--------|-------|
| Supportive care | Standard | Manage symptoms |
| Liver transplantation | Used in some cases | For hepatic failure |
| Coenzyme Q10 | Empiric | May help some patients |
| Riboflavin | Empiric | May help some patients |
| L-carnitine | Empiric | For metabolic support |

Emerging Therapies

Nucleotide Supplementation

dNTP supplementation: May support mtDNA maintenance
Nucleoside therapy: Precursor supplementation approaches

Gene Therapy

Viral vector delivery: Gene replacement approaches
CRISPR-based: Potential future applications
Mitochondrial targeting: Challenges with mitochondrial gene delivery

Small Molecule Approaches

Mitochondrial biogenesis: Compounds that increase mitochondrial mass
Antioxidants: Reduce oxidative stress
Metabolic modulators: Support energy metabolism

Biomarker Development

mtDNA copy number: Diagnostic and monitoring biomarker
Lactate: Metabolic biomarker
Functional assays: Respiratory chain activity

Animal Models

Mouse Models

| Model | Phenotype | Relevance |
|-------|-----------|-----------|
| MpV17 knockout | mtDNA depletion, liver failure | Severe, early death |
| Conditional KO | Tissue-specific deficiency | Modeling |
| Heterozygous | Subtle defects | Carrier state |

Zebrafish Models

Morpholino knockdown: Developmental defects
CRISPR models: Phenocopy human disease
Drug screening: Identify therapeutic compounds

Invertebrate Models

Drosophila: Homolog in mitochondrial function
C. elegans: mtDNA maintenance pathways

Protein Interactions

Mitochondrial Proteins

| Partner | Interaction | Outcome |
|---------|-------------|---------|
| TFAM | Indirect | mtDNA packaging |
| POLG | Indirect | Replication |
| Twinkle | Indirect | Helicase function |
| Mitochondrial complex I | Indirect | Respiratory chain |

Signaling Pathways

Mitochondrial dynamics: Interactions with fission/fusion proteins
Apoptosis: Involvement in cell death pathways
Metabolic signaling: Integration with cellular metabolism

Clinical Significance

Diagnosis

Genetic testing: Sequencing of MPV17 coding region
mtDNA copy number: Quantitative PCR assessment
Clinical evaluation: Multi-system assessment

Prognosis

Early onset: More severe phenotype
Liver involvement: Major determinant of outcome
Neurological involvement: Progressive course

Family Counseling

Autosomal recessive: 25% recurrence risk for carrier parents
Carrier testing: Available for at-risk family members
Prenatal testing: Possible for known mutations
Preimplantation diagnosis: Option for affected families

Population Genetics

Genetic Variation

| Variant Type | Frequency | Pathogenicity |
|--------------|-----------|---------------|
| Pathogenic mutations | Rare | Disease-causing |
| Variants of uncertain significance | Rare | Requires interpretation |
| Common polymorphisms | Common | Generally benign |

Disease Incidence

Overall MTDPS: 1 in 100,000-1,000,000
MPV17 proportion: Significant portion of hepatocerebral MTDPS

Evolutionary Conservation

Species Conservation

MPV17 is highly conserved across eukaryotes:

| Species | Homology | Notes |
|---------|----------|-------|
| Human | 100% | Reference |
| Mouse | 92% | Highly similar |
| Zebrafish | 85% | Functional ortholog |
| Drosophila | 70% | Homolog exists |
| Yeast | 50% | Functional ortholog |
| C. elegans | 45% | Partial conservation |

References

[Spinazzi M et al., MPV17 mutations causing mtDNA depletion syndrome (2009)](https://pubmed.ncbi.nlm.nih.gov/19272351/)

[El-Hattab AW et al., MPV17-related mitochondrial DNA depletion syndrome (2017)](https://pubmed.ncbi.nlm.nih.gov/28466820/)

[Wong LJ et al., Mutations in MPV17 cause mtDNA depletion syndrome (2007)](https://pubmed.ncbi.nlm.nih.gov/17989366/)

[Karadimas CL et al., MPV17 mutation causing mtDNA depletion (2006)](https://pubmed.ncbi.nlm.nih.gov/17018282/)

[Uusimaa J et al., Clinical manifestations in MPV17 deficiency (2013)](https://pubmed.ncbi.nlm.nih.gov/24064152/)

[Parisi MA et al., MPV17 and mtDNA depletion: a complex story (2009)](https://pubmed.ncbi.nlm.nih.gov/19560526/)

[Dalla Rosa I et al., MPV17 deficiency leads to mitochondrial dysfunction (2017)](https://pubmed.ncbi.nlm.nih.gov/28279761/)

[Kaji S et al., MTDPS with MPV17 mutations in siblings (2018)](https://pubmed.ncbi.nlm.nih.gov/29397076/)

[Blei AT et al., Mitochondrial DNA depletion and liver failure (2005)](https://pubmed.ncbi.nlm.nih.gov/16080614/)

[Taylor RW et al., Mitochondrial DNA mutations in human disease (2014)](https://pubmed.ncbi.nlm.nih.gov/24797621/)

[Rustin P et al., Mitochondria from patients with mitochondrial diseases (2003)](https://pubmed.ncbi.nlm.nih.gov/12620209/)

[Suomalainen A et al., Therapeutic approaches to MTDPS (2011)](https://pubmed.ncbi.nlm.nih.gov/21484196/)

[Kopinsky S et al., Mitochondrial dynamics in MPV17 deficiency (2018)](https://pubmed.ncbi.nlm.nih.gov/29797052/)

[Hazzalini MA et al., MPV17 and mitochondrial quality control (2019)](https://pubmed.ncbi.nlm.nih.gov/31173809/)

[Moreno M et al., Mitochondrial DNA maintenance defects and neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31147643/)

[Falletta P et al., Mitochondrial nucleoid dynamics and disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29467446/)

[Barg N et al., MPV17 in aging and neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32147824/)

[Chaves J et al., Mitochondrial dysfunction in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32172572/)

[Kruszewski K et al., Mitochondrial dynamics in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32053442/)

[Graziano GE et al., Mitochondrial quality control in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33419623/)

[Kimura S et al., MPV17 and metabolic stress response (2021)](https://pubmed.ncbi.nlm.nih.gov/33738561/)

[Anton L et al., MTDPS: from genetics to therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/30666788/)

[Lopez A et al., Mitochondrial biogenesis and mtDNA replication (2021)](https://pubmed.ncbi.nlm.nih.gov/33838915/)

Pathway Diagram

The following diagram shows the key molecular relationships involving MPV17 Gene - MPV17 Mitochondrial Inner Membrane Protein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

MPV17 Gene - MPV17 Mitochondrial Inner Membrane Protein

MPV17 Gene - MPV17 Mitochondrial Inner Membrane Protein

Introduction

MPV17 Gene - MPV17 Mitochondrial Inner Membrane Protein

Introduction

Overview

Molecular Function

Protein Structure

Role in Mitochondrial DNA Maintenance

Nucleotide Pool Regulation

mtDNA Replication Complex

Mitochondrial Dynamics

Interaction Network

Role in Disease

Mitochondrial DNA Depletion Syndrome

Genetics

Clinical Features

Pathogenesis

Alzheimer's Disease

Mitochondrial Dysfunction

Molecular Mechanisms

Therapeutic Implications

Parkinson's Disease

Mitochondrial Involvement

Mechanisms

Research Evidence

Other Mitochondrial Disorders

Expression Pattern

Tissue Distribution

Cellular Localization

Developmental Regulation

Therapeutic Implications

Current Treatment Approaches

Emerging Therapies

Nucleotide Supplementation

Gene Therapy

Small Molecule Approaches

Biomarker Development

Animal Models

Mouse Models

Zebrafish Models

Invertebrate Models

Protein Interactions

Mitochondrial Proteins

Signaling Pathways

Clinical Significance

Diagnosis

Prognosis

Family Counseling

Population Genetics

Genetic Variation

Disease Incidence

Evolutionary Conservation

Species Conservation

See Also

References

Pathway Diagram